NextCure, Inc. has presented new preclinical data at the Brittle Bone Society Meeting showing that its novel anti-Siglec-15 antibody, NC605, significantly improves bone microarchitecture and reduces ...

Wif1 overexpression accelerated osteogenic differentiation by activating genes related to late-stage osteogenic differentiation and mitophagy processes. Moreover administering Wif1-overexpressing ...

Researchers have successfully regenerated damaged skull bones in mice by creating a freestanding, biomimetic scaffold that combines a piezoelectric framework and the growth-promoting properties of a ...

Schematic diagram illustrating how transplanted young mitochondria activate the AKAP1/cAMP/PKA pathway in aged PDLSCs, restoring mitochondrial membrane potential (ΔΨm), reducing ROS, and enhancing ...

NOVATO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE) today announced results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis ...

Angitia Biopharmaceuticals has unveiled its second mega-round in 14 months, revealing a $130 million series D financing that positions the biotech to take three bone disease prospects deeper into the ...

Bent bone dysplasia (BBD) is a perinatal-lethal skeletal disorder caused by pathogenic FGFR2 mutations that disrupt bone formation, leading to bent long bones, osteopenia, and craniosynostosis. Bent ...